Selección · Salud

Biotech

Por InspectStocksPublished 14 oct 202619 companies0 followers

Drug developers with approved medicines, built mainly on biologic and genetic science.

Agrupadas con ayuda de un modelo de IA y revisadas por nuestros editores. La línea bajo cada empresa explica por qué está aquí.

Download image

Tarjetas Niveles

Los precios de las acciones son el cierre del 11 nov 2026, del feed de la bolsa IEX.

Grade mix

A 8B 4C 5D 1F 1

Revenue growing

18 of 19

Free cash flow growing

13 of 18

Median price move, 1 year

+29,0 %

Sort by

VRTXVERTEX PHARMACEUTICALS INC / MA
BiotechnologyMarket cap 138,7B US$P/E 35,22
547,02 US$+26,0 %1Y
Since added +12,7 %
B+
Crecimiento y caja
Creciendo con fuerza
Business trend
Estable
Business quality
Fuerte
Getting better
Mejorando
Revenue
13B US$+10,5 %
Profit
4B US$+8,2 %
Free cash flow
3,2B US$-4,0 %
Discuss
Why it is here: Develops and sells cystic fibrosis and other medicines
REGNREGENERON PHARMACEUTICALS, INC.
BiotechnologyMarket cap 101,3B US$P/E 21,18
959,45 US$+41,5 %1Y
Since added +27,4 %
C+
Crecimiento y caja
Creciendo
Business trend
Acelerando
Business quality
Fuerte
Getting better
Mejorando
Revenue
16,9B US$+18,6 %
Profit
4,8B US$+5,2 %
Free cash flow
3,8B US$-9,4 %
Discuss
Why it is here: Develops and sells antibody therapies for eye, allergy and cancer conditions
GILDGILEAD SCIENCES, INC.
Drug manufacturers generalMarket cap 210,5B US$Sin PER (pérdida operativa)
169,73 US$+40,9 %1Y
Since added +14,8 %
A
Crecimiento y caja
Creciendo con fuerza
Business trend
Estable
Business quality
Mixta
Getting better
Mejorando
Revenue
31B US$+6,5 %
Profit
-3,9B US$-147,6 %
Free cash flow
13,8B US$+50,4 %
Discuss
Why it is here: Sells medicines for HIV, liver disease and cancer
ALNYALNYLAM PHARMACEUTICALS, INC.
BiotechnologyMarket cap 21,4B US$P/E 68,58
159,80 US$-64,7 %1Y
Since added -28,6 %
B+
Crecimiento y caja
Creciendo con fuerza
Business trend
Desacelerando
Business quality
Fuerte
Getting better
Mejorando
Revenue
3,7B US$+65,2 %
Profit
2,6B US$+2136,9 %
Free cash flow
465,4M US$+1192,7 %
Discuss
Why it is here: Develops and sells RNAi therapeutics
BIIBBIOGEN INC.
Drug manufacturers generalMarket cap 37,5B US$P/E 109,22
253,39 US$+56,9 %1Y
Since added +10,7 %
A
Crecimiento y caja
Creciendo con fuerza
Business trend
Estable
Business quality
Sólida
Getting better
Mixto
Revenue
10,3B US$+2,3 %
Profit
347,5M US$-78,4 %
Free cash flow
2,1B US$-10,1 %
Discuss
Why it is here: Develops and sells therapies for neurological diseases
INSMINSMED INC
BiotechnologyMarket cap 26,5B US$Sin PER (pérdida operativa)
120,64 US$-37,9 %1Y
Since added +24,7 %
C-
Crecimiento y caja
Creciendo
Business trend
Estable
Business quality
Débil
Getting better
Mixto
Revenue
1,5B US$+240,0 %
Profit
-605,6M US$+48,8 %
Free cash flow
-627,6M US$+30,7 %
Discuss
Why it is here: Develops and sells therapies for rare lung diseases
UTHRUnited Therapeutics Corporation
Drug manufacturers specialty and genericMarket cap 25,4B US$P/E 22,48
595,58 US$+29,0 %1Y
Since added +9,6 %
C+
Crecimiento y caja
Creciendo con fuerza
Business trend
Desacelerando
Business quality
Fuerte
Getting better
Mejorando con fuerza
Revenue
3,2B US$+1,9 %
Profit
1,2B US$-3,2 %
Free cash flow
867,2M US$-22,7 %
Discuss
Why it is here: Sells therapies for pulmonary arterial hypertension
NBIXNEUROCRINE BIOSCIENCES, INC.
Drug manufacturers specialty and genericMarket cap 17,6B US$P/E 25,87
174,35 US$+18,7 %1Y
Since added +29,0 %
A+
Crecimiento y caja
Creciendo con fuerza
Business trend
Acelerando
Business quality
Fuerte
Getting better
Mejorando
Revenue
3,7B US$+38,0 %
Profit
702,5M US$+64,1 %
Free cash flow
1B US$+75,3 %
Discuss
Why it is here: Develops and sells therapies for neurological and endocrine disorders
MRNAModerna, Inc.
BiotechnologyMarket cap 100,6B US$Sin PER (pérdida operativa)
248,70 US$+831,1 %1Y
Since added +15,0 %
C-
Crecimiento y caja
Creciendo
Business trend
Acelerando
Business quality
Débil
Getting better
Deteriorándose
Revenue
2,5B US$+13,1 %
Profit
-2,8B US$+10,5 %
Free cash flow
-2B US$+25,7 %
Discuss
Why it is here: Develops mRNA vaccines and therapies
BMRNBioMarin Pharmaceutical Inc
BiotechnologyMarket cap 11,3B US$No P/E
58,32 US$+5,4 %1Y
Since added +7,3 %
B
Crecimiento y caja
Creciendo con fuerza
Business trend
Estable
Business quality
Mixta
Getting better
Mejorando
Revenue
3,7B US$+18,1 %
Profit
-19,1M US$-103,7 %
Free cash flow
557,9M US$-33,0 %
Discuss
Why it is here: Develops and sells therapies for rare genetic diseases
INCYINCYTE CORPORATION
BiotechnologyMarket cap 24,9B US$P/E 65,01
122,23 US$+12,9 %1Y
Since added +12,6 %
C
Beneficio y valor contable
Creciendo
Business quality
Mixta
Getting better
Mejorando con fuerza
Revenue
6B US$+24,9 %
Profit
403,4M US$-66,1 %
Free cash flow
892,1M US$No comparable year
Discuss
Why it is here: Develops and sells oncology and inflammation therapies
EXELEXELIXIS, INC.
BiotechnologyMarket cap 17,3B US$P/E 21,17
70,71 US$+62,2 %1Y
Since added +18,8 %
A+
Crecimiento y caja
Creciendo con fuerza
Business trend
Estable
Business quality
Fuerte
Getting better
Mejorando
Revenue
2,5B US$+9,1 %
Profit
885,1M US$+30,6 %
Free cash flow
1,2B US$+48,9 %
Discuss
Why it is here: Develops and sells cancer therapies
BNTXBioNTech SE
BiotechnologyMarket cap 22B US$Sin PER (pérdida operativa)
87,64 US$-21,5 %1Y
Since added -1,5 %
F
Crecimiento y caja
Mixto
Business trend
Contrayéndose
Business quality
Mixta
Getting better
Mejorando
Revenue
2,7B US$-23,2 %
Profit
-1,6B US$-157,7 %
Free cash flow
314M US$+456,5 %
Discuss
Why it is here: Develops mRNA vaccines and cancer therapies
JAZZJazz Pharmaceuticals plc
BiotechnologyMarket cap 15,9B US$P/E 80,84
248,18 US$+81,5 %1Y
Since added +18,0 %
A
Crecimiento y caja
Creciendo con fuerza
Business trend
Estable
Business quality
Mixta
Getting better
Mejorando
Revenue
4,7B US$+13,5 %
Profit
206M US$+155,9 %
Free cash flow
1,6B US$+21,3 %
Discuss
Why it is here: Develops and sells neuroscience and oncology therapies
HALOHALOZYME THERAPEUTICS, INC.
BiotechnologyMarket cap 11,6B US$P/E 25,36
101,69 US$+44,0 %1Y
Since added -7,2 %
A+
Crecimiento y caja
Creciendo con fuerza
Business trend
Estable
Business quality
Fuerte
Getting better
Mejorando
Revenue
1,8B US$+45,0 %
Profit
485,4M US$-18,5 %
Free cash flow
885,9M US$+47,1 %
Discuss
Why it is here: Licenses drug delivery technology and sells enzyme-based therapies
ASNDAscendis Pharma A/S
BiotechnologyMarket cap 16,1B US$Sin PER (pérdida operativa)
259,10 US$+30,1 %1Y
Since added +16,0 %
D
Beneficio y valor contable
Mixto
Business quality
Mixta
Getting better
Mejorando
Revenue
1,2B US$+113,4 %
Profit
-254,8M US$+39,7 %
Free cash flow
-293,2M US$+54,2 %
Discuss
Why it is here: Develops and sells endocrinology rare disease therapies
BBIOBridgeBio Pharma, Inc.
BiotechnologyMarket cap 15,5B US$Sin PER (pérdida operativa)
79,53 US$+20,1 %1Y
Since added +25,6 %
B
Crecimiento y caja
Creciendo con fuerza
Business trend
Estable
Business quality
Mixta
Getting better
Deteriorándose
Revenue
945,5M US$+167,3 %
Profit
-573,8M US$+28,6 %
Free cash flow
-369,8M US$+36,9 %
Discuss
Why it is here: Develops therapies for genetic diseases
CORTCORCEPT THERAPEUTICS INC
BiotechnologyMarket cap 8,2B US$P/E 58,68
74,52 US$-4,9 %1Y
Since added -36,7 %
A+
Crecimiento y caja
Creciendo con fuerza
Business trend
Acelerando
Business quality
Fuerte
Getting better
Mixto
Revenue
963,6M US$+30,0 %
Profit
162,3M US$+52,9 %
Free cash flow
194,6M US$+19,2 %
Discuss
Why it is here: Develops and sells cortisol-modulating therapies
KRYSKrystal Biotech, Inc.
BiotechnologyMarket cap 9,2B US$P/E 41,90
308,82 US$+52,1 %1Y
Since added -3,9 %
A+
Crecimiento y caja
Creciendo con fuerza
Business trend
Estable
Business quality
Fuerte
Getting better
Mejorando
Revenue
470M US$+26,0 %
Profit
225,2M US$+13,2 %
Free cash flow
310,1M US$+87,3 %
Discuss
Why it is here: Develops and sells topical gene therapies for rare diseases

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.